Regulations in the United States for cell transplantation clinical trials in neurological diseases

• 作者: Baoyang Hu He Zhu Jason S. Meyer Qi Gu Weifang Han Yuanqing Tan Zhongwen Li
• 来源期刊: 临床转化神经医学(英文版)
• 学科: 医学
• 年，卷（期）: 2015,（2）
• 页码范围: 114-124
• 页数: 11页
• 分类号: R741

摘要

Objective: This study aimed to use a systematic approach to evaluate the current utilization, safety, and effectiveness of cell therapies for neurological diseases in human. And review the present regulations, considering United States(US) as a representative country, for cell transplantation in neurological disease and discuss the challenges facing the field of neurology in the coming decades. Methods: A detailed search was performed in systematic literature reviews of cellular‐based therapies in neurological diseases, using Pub Med, web of science, and clinical trials. Regulations of cell therapy products used for clinical trials were searched from the Food and Drug Administration(FDA) and the National Institutes of Health(NIH).Results: Seven most common types of cell therapies for neurological diseases have been reported to be relatively safe with varying degrees of neurological recovery.And a series of regulations in US for cellular therapy was summarized including preclinical evaluations, sourcing material, stem cell manufacturing and characterization,cell therapy product, and clinical trials. Conclusions: Stem cell‐based therapy holds great promise for a cure of such diseases and will value a growing population of patients. However, regulatory permitting activity of the US in the sphere of stem cells, technologies of regenerative medicine and substitutive cell therapy are selective, theoretical and does not fit the existing norm and rules. Compiled well‐defined regulations to guide the application of stem cell products for clinical trials should be formulated.